Role of extracellular signal-regulated kinase (ERK)1/2 in multicellular resistance to docetaxel in MCF-7 cells

International Journal of Oncology

Volumn 37, Issue 3, 2010, Pages 655-661

  Jeong, Eui Kyong ^a   Lee, Su Yeon ^a   Jeon, Hyun Min ^a   Ju, Min Kyung ^a   Kim, Cho Hee ^a   Kang, Ho Sung ^a  

^a Pusan National University   (South Korea)

Author keywords

Docetaxel; ERK1 2; Multicellular resistance; Multicellular tumour spheroids; Necrosis

Indexed keywords

DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; MULTICELLULAR SPHEROID; NECROSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-AKT; SPHEROIDS, CELLULAR; TAXOIDS;

EID: 77956510367     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000714     Document Type: Article

References (39)

1. Raguz S and Yague E: Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 99: 387-391, 2008.
2. Wilson TR, Longley DB and Johnston PG: Chemoresistance in solid tumours. Ann Oncol 17 (Suppl. 10): S315-S324, 2006.
3. Meads MB, Gatenby RA and Dalton WS: Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9: 665-674, 2009.
4. Yap TA, Carden CP and Kaye SB: Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9: 167-181, 2009.
5. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
6. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y and Maehara Y: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8: 27-36, 2008.
7. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
8. Balmanno K and Cook SJ: Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16: 368-377, 2009.
9. Jiang BH and Liu LZ: Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11: 63-76, 2008.
10. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 6: 2092-2102, 2007.
11. Kisucka J, Barancik M, Bohacova V and Breier A: Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen Physiol Biophys 20: 439-444, 2001. (Pubitemid 34196160)
12. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EW, Steelman LS, Basecke J, Troppmair J, Libra M, Nicoletti F, Molton S, McMahon M, Evangelisti C and Martelli AM: Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 22: 2080-2090, 2008.
13. Wouters BG and Koritzinsky M: Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8: 851-864, 2008.
14. Barbone D, Yang TM, Morgan JR, Gaudino G and Broaddus VC: Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 283: 13021-13030, 2008.
15. Friedrich J, Seidel C, Ebner R and Kunz-Schughart LA: Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4: 309-324, 2009.
16. Gottfried E, Kunz-Schughart LA, Andreesen R and Kreutz M: Brave little world: spheroids as an in vitro model to study tumour-immune-cell interactions. Cell Cycle 5: 691-695, 2006.
17. Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, Panda AK and Labhasetwar V: 3-D tumour model for in vitro evaluation of anticancer drugs. Mol Pharm 5: 849-862, 2008.
18. Desoize B and Jardillier J: Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36: 193-207, 2000.
19. West GW, Weichselbaum R and Little JB: Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumour resistance to adjuvant chemotherapy. Cancer Res 40: 3665-3668, 1980.
20. Xing H, Wang S, Weng D, Chen G, Yang X, Zhou J, Xu G, Lu Y and Ma D: Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep 17: 117-122, 2007.
21. Gallardo-Perez JC, Espinosa M, Ceballos-Cancino G, Daniel A, Rodriguez-Enriquez S, Aviles A, Moreno-Sanchez R, Melendez-Zajgla J and Maldonado V: NF-kappa B is required for the development of tumour spheroids. J Cell Biochem 108: 169-180, 2009.
22. Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899, 2004.
23. Bristow RG and Hill RP: Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8: 180-192, 2008.
24. Brown JM: Tumour microenvironment and the response to anticancer therapy. Cancer Biol Ther 1: 453-458, 2002.
25. Edwards JG, Swinson DE, Jones JL, Muller S, Waller DA and O'Byrne KJ: Tumour necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 124: 1916-1923, 2003.
26. Langner C, Hutterer G, Chromecki T, Leibl S, Rehak P and Zigeuner R: Tumour necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. J Urol 176: 910-914, 2006.
27. Leibovitch I, Lev R, Mor Y, Golomb J, Dotan ZA and Ramon J: Extensive necrosis in renal cell carcinoma specimens: potential clinical and prognostic implications. Isr Med Assoc J 3: 563-565, 2001.
28. Vakkila J and Lotze MT: Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4: 641-648, 2004. (Pubitemid 39025049)
29. Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342, 2005.
30. Brown GD: Sensing necrosis with Mincle. Nat Immunol 9: 1099-1100, 2008.
31. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L and Kroemer G: Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14: 364-375, 2009.
32. McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785: 96-132, 2008.
33. Hernandez-Vargas H, Palacios J and Moreno-Bueno G: Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 26: 2902-2913, 2007.
34. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K and Ochiya T: RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 14: 939-948, 2008.
35. Jiang CC, Yang F, Thorne RF, Zhu BK, Hersey P and Zhang XD: Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia 11: 436-447, 2009.
36. Navolanic PM, Lee JT and McCubrey JA: Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway. Cancer Biol Ther 2: 677-678, 2003.
37. Kim CH, Han SI, Lee SY, Youk HS, Moon JY, Duong HQ, Park MJ, Joo YM, Park HG, Kim YJ, Yoo MA, Lim SC and Kang HS: Protein kinase C-ERK1/2 signal pathway switches glucose depletion-induced necrosis to apoptosis by regulating superoxide dismutases and suppressing reactive oxygen species production in A549 lung cancer cells. J Cell Physiol 211: 371-385, 2007.
38. Ivascu A and Kubbies M: Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol 31: 1403-1413, 2007.
39. Mueller-Klieser WF and Sutherland RM: Influence of convection in the growth medium on oxygen tensions in multicellular tumour spheroids. Cancer Res 42: 237-242, 1982.